Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication

被引：38

作者：

Bellet, Meritxell ^{[1
,2
]}

Ahmad, Faten ^{[3
]}

Villanueva, Rafael ^{[4
]}

Valdivia, Carolina ^{[1
]}

Palomino-Doza, Julian ^{[5
]}

Ruiz, Ada ^{[6
,7
]}

Gonzalez, Xavier ^{[8
]}

Adrover, Encarna ^{[9
]}

Azaro, Analia ^{[2
,10
]}

Valls-Margarit, Maria ^{[11
]}

Lluis Parra, Josep ^{[11
]}

Aguilar, Juan ^{[10
,12
]}

Vidal, Maria ^{[13
,14
]}

Martin, Anastasi ^{[15
]}

Gavila, Joaquin ^{[16
]}

Escriva-de-Romani, Santiago ^{[1
,2
]}

Perello, Antonia ^{[17
]}

Hernando, Cristina ^{[18
,19
]}

Lahuerta, Ainhara ^{[20
]}

Zamora, Pilar ^{[21
]}

Reyes, Victoria ^{[22
]}

Alcalde, Maria ^{[3
]}

Masanas, Helena ^{[11
]}

Celiz, Pamela ^{[11
]}

Ruiz, Isabel ^{[3
]}

Gil, Miguel ^{[23
]}

Angel Segui, Miguel ^{[24
]}

de la Pena, Lorena ^{[11
]}

机构：

[1] Vall dHebron Univ Hosp, Passeig Vall dHebron 119-129, Barcelona, Spain

[2] Vall dHebron Inst Oncol, Passeig Vall dHebron 119-129, Barcelona, Spain

[3] Vall dHebron Univ Hosp, Vall dHebron Res Inst, Barcelona, Spain

[4] Hosp Moises Broggi, Inst Catala Oncol, Barcelona, Spain

[5] Hosp Univ 12 Octubre, Hereditary Cardiopathies Unit, Madrid, Spain

[6] Hosp del Mar, Inst Neuropsiquiatria & Addict, Barcelona, Spain

[7] Hosp del Mar, Med Res Inst, Barcelona, Spain

[8] Hosp Gen Cataluna, SOLTI, Inst Oncol Dr Rosell, Barcelona, Spain

[9] Complejo Hosp Univ Albacete, Serv Oncol Med, Albacete, Spain

[10] Vall dHebron Univ Hosp, Med Oncol Dept, Barcelona, Spain

[11] SOLTI, Barcelona, Spain

[12] Vall dHebron Univ Hosp, Infect Dis Dept, Barcelona, Spain

[13] Inst Invest Biomed August Pi & Sunyer, Hosp Clin Barcelona, Barcelona, Spain

[14] Inst Invest Biomed August Pi & Sunyer, Translat Genom & Targeted Therapeut Solid Tumors, Barcelona, Spain

[15] Vall dHebron Univ Hosp, Unitat Cures Palliat, Barcelona, Spain

[16] Fdn Inst Valenciano Oncol, Valencia, Spain

[17] Hosp Univ Son Espases, Palma De Mallorca, Spain

[18] Hosp Clin Univ Valencia, Incl Inst Invest Sanitaria, Valencia, Spain

[19] Ctr Invest Biomed Red Canc, Valencia, Spain

[20] Fdn Onkol, Donostia San Sebastian, Spain

[21] Hosp Univ La Paz, Serv Oncol Med, Madrid, Spain

[22] Vall dHebron Univ Hosp, Radiat Oncol Dept, Barcelona, Spain

[23] IDIBELL Inst Invest Biomed Bellvitge, Inst Catala Oncol, Barcelona, Spain

[24] Hosp Univ, Parc Tauli Sabadell, Barcelona, Spain

来源：

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY | 2019年 / 11卷

关键词：

CDK inhibitors; palbociclib; ribociclib; breast cancer; P-GLYCOPROTEIN INHIBITION; DRUG-DRUG INTERACTIONS; INDUCED LIVER-INJURY; CDK4/6; INHIBITOR; MULTIDRUG-RESISTANCE; PHASE-I; ALTERNATIVE MEDICINE; PLUS LETROZOLE; QT; CHEMOTHERAPY;

D O I：

10.1177/1758835919833867

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Drug-drug interactions are of significant concern in clinical practice in oncology, particularly in patients receiving Cyclin-dependent kinase (CDK) 4/6 inhibitors, which are typically exposed to long-term regimens. This article presents the highlights from the 'First Workshop on Pharmacology and Management of CDK4/6 Inhibitors: Consensus about Concomitant Medications'. The article is structured into two modules. The educational module includes background information regarding drug metabolism, corrected QT (QTc) interval abnormalities, management of psychotropic drugs and a comprehensive review of selected adverse effects of palbociclib and ribociclib. The collaborative module presents the conclusions of the five working groups, each of which comprised five experts from different fields. From these conclusions positive lists of drugs for treating common comorbid conditions that can be safely administered concomitantly with palbociclib and/or ribociclib were developed.

引用

页数：43

共 109 条

[1] Adike Abimbola, 2016, Case Rep Gastroenterol, V10, P381
[2] Citalopram, escitalopram and prolonged QT: Warning or alarm?
Alvarez, Enric
Vieira, Sara
Garcia-Moll, Xavier
[J]. REVISTA DE PSIQUIATRIA Y SALUD MENTAL, 2014, 7 (03): : 147 - 150
[3] P-glycoprotein Inhibition for Optimal Drug Delivery
Amin, Md. Lutful
[J]. DRUG TARGET INSIGHTS, 2013, 7 : 27 - 34
[4] [Anonymous], 2018, COMB FULV HORM REC H
[5] [Anonymous], 2018, AD CANC PAIN NCCN CL
[6] [Anonymous], 2013, MAGNESIA CINFA SUMMA
[7] [Anonymous], SUMMARY PRODUCT CHAR
[8] [Anonymous], ANN ONCOL S5
[9] [Anonymous], 2015, HIGHL PRESCR INF
[10] [Anonymous], 2018, STUD PALB PD 0332991

← 1 2 3 4 5 6 7 8 9 10 →